NIAID Banner Logo Image

HBV Citations List: May, 2022

Literature Citations

1. Design, Synthesis, and Biological Evaluation of Novel (E)-1-Arylethan-1-one O-((3-arylisoxazol-5-yl) methyl) oxime Derivatives as Potent Non-nucleoside HBV Inhibitors. Huang, Y.H., N. Liu, Q.Y. Ning, M. Zhou, N. Zang, T.Y. Liang, and W.X. Wei. Journal of Molecular Structure, 2022. 1260: 132789. ISI[000791330400001].
[WOS]. HBV_05_2022.

2. Inhibitory Activities of Ranunculus japonicus Thunb. Ethanol Extract against Hepatitis B Virus. Luo, M., Z. Chen, M. Liu, Q. Liang, R. Han, Z. Liang, Z. Ye, and K. Liu. Journal of Medical Virology, 2022. 94(6): p. 2727-2735. PMID[35075662].
[PubMed]. HBV_05_2022.

3. Novel anti-Hepatitis B Virus-active Catechin and Epicatechin from Rhus tripartita. Parvez, M.K., M.S. Al-Dosari, M.A.S. Abdelwahid, A.S. Alqahtani, and A.R. Alanzi. Experimental and Therapeutic Medicine, 2022. 23(6): 398. PMID[35619632]. PMCID[PMC9115632].
[PubMed]. HBV_05_2022.

4. Dysregulation of Hepatitis B Virus Nucleocapsid Assembly in Vitro by RNA-binding Small Ligands. Patel, N., F. Abulwerdi, F. Fatehi, I.W. Manfield, S. Le Grice, J.S. Schneekloth, Jr., R. Twarock, and P.G. Stockley. Journal of Molecular Biology, 2022. 434(10): 167557. PMID[35341740]. PMCID[PMC7612645].
[PubMed]. HBV_05_2022.

5. Naturally Occurring HMGB1 Inhibitor Delineating the anti-Hepatitis B Virus Mechanism of Glycyrrhizin via in Vitro and in Silico Studies. Sultan, A., M. Afroz, S.A. Bhat, Z.I. Siddiqui, Z.A. Parray, S.A. Azam, S.R. Farooqui, and S.N. Kazim. Journal of Molecular Liquids, 2022. 356: 119029. ISI[000790607100004].
[WOS]. HBV_05_2022.

6. A Broad-spectrum Nanobody Targeting the C-terminus of the Hepatitis B Surface Antigen for Chronic Hepatitis B Infection Therapy. Wang, Y., Y. Mei, Z. Ao, Y. Chen, Y. Jiang, X. Chen, R. Qi, B. Fu, J. Tang, M. Fang, M. You, T. Zhang, Q. Yuan, W. Luo, and N. Xia. Antiviral Research, 2022. 199: 105265. PMID[35183645].
[PubMed]. HBV_05_2022.

7. Systematic Optimization of Host-directed Therapeutic Targets and Preclinical Validation of Repositioned Antiviral Drugs. Xie, D., S. He, L. Han, L. Wu, H. Huang, H. Tao, P. Zhou, X. Shi, H. Bai, and X. Bo. Briefings in Bioinformatics, 2022. 23(3): bbac047. PMID[35238349]. PMCID[PMC9116211].
[PubMed]. HBV_05_2022.

Patent Citations

8. Spiro[3.3]Heptane Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Lin, X., J. Wang, H. Yun, and X. Zheng. Patent. 2022. 2021-EP82540 2022112188: 73pp.
[Patent]. HBV_05_2022.

9. Aromatic Spiro Ring Amide Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Infection.Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82593 2022112207: 167pp.
[Patent]. HBV_05_2022.

10. Aryloxazolo Spiral Ring Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82396 2022112140: 122pp.
[Patent]. HBV_05_2022.

11. N-Substituted 4-(5-Phenyl-1,3,4-oxadiazol-2-yl)aniline for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82393 2022112139: 45pp.
[Patent]. HBV_05_2022.

12. N-[(1,3-Benzoxazol-2-yl)-heterocycle]amide Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82470 2022106680: 134pp.
[Patent]. HBV_05_2022.

13. N-Substituted 4-(1,3-Aryloxazolo-2-Yl)phenyl Compounds for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82237 2022106589: 77pp.
[Patent]. HBV_05_2022.

14. 2-Phenylbenzotriazol-5-amine Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus (HBV) Infection.Lin, X., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82236 2022106588: 68pp.
[Patent]. HBV_05_2022.

15. Preparation of Bicyclic Compounds as Antiviral Agents. Vendeville, S., P.J.-M.B. Raboisson, and D. McGowan. Patent. 2022. 2021-17451462 20220119385: 66pp.
[Patent]. HBV_05_2022.

16. Bicyclo[1.1.1]pentane Compounds for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Wang, J., H. Yun, B. Zhang, and X. Zheng. Patent. 2022. 2021-EP81756 2022106375: 102pp.
[Patent]. HBV_05_2022.

17. Aromatic Bridged Ring Amide Derivatives for the Treatment and Prophylaxis of Hepatitis B Virus Infection. Yun, H., B. Zhang, and X. Zheng. Patent. 2022. 2021-EP82590 2022112205: 89pp.
[Patent]. HBV_05_2022.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: January 2024